The Online Investor
Grocery & Drug Stores M&A image Grocery & Drug Stores M&A » By The Online Investor Staff, updated Thu., May. 13, 6:49 PM Recent mergers and acquisitions in the Grocery & Drug Stores M&A category.

Slide #16. CVS Caremark Coram Infusion Business from Apria Healthcare

Acquirer: CVS Caremark (NYSE:CVS)
Acquiree: Coram Infusion Business from Apria Healthcare
Details: CVS Caremark (NYSE: CVS) today announced that it has completed the acquisition of Coram LLC ("Coram"), the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. Coram is one of the nation's largest providers of comprehensive infusion services, caring for approximately 165,000 patients annually. Coram has 4,600 employees, including 600 nurses, 350 pharmacists and 250 dietitians, operating primarily through 85 branch locations and six centers of excellence for patient intake.

CVS Health is a health services company. Co.'s segments include: Pharmacy Services, which provides pharmacy benefit management solutions, including plan design offerings and administration, formulary management, and retail pharmacy network management services; Retail/Long-Term Care (LTC), which sells prescription drugs and various health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics and conducts LTC pharmacy operations; and Health Care Benefits, which provides voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, and dental and behavioral health plans.

CVS Health SEC Filing Email Alerts Service


Open the CVS Page at The Online Investor »

Company Name: 
CVS Health Corporation
Stock buyback: 
CVS buyback
Website: 
www.cvshealth.com
Sector: 
Diagnostics
Number of ETFs Holding CVS: 
115
Total Market Value Held by ETFs: 
$11.75B
Total Market Capitalization: 
$111.08B
% of Market Cap. Held by ETFs: 
10.58%
 

Open the CVS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.25 out of 4)
40th percentile
(ranked lower than approx. 60% of all stocks covered)

Analysts' Target Price:
CVS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Grocery & Drug Stores M&A - Slide 16 of 48 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.